Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Board Establishes Office of the CEO, Conducts Search for Successor
Raises 2023 Revenue Guidance
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson.
CareDx will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, Chief Financial Officer Abhishek Jain and President of Patient and Testing Services Alexander Johnson. The Board of Directors has initiated a search for a permanent CEO and is considering both internal and external candidates.
"I look forward to working with Abhishek and Alex on an interim basis to ensure we continue to execute our strategic plans while the Board conducts a comprehensive search to identify a successor," said Mr. Goldberg. "We thank Dr. Seeto for his dedication to our company and our mission during his tenure, and we wish him all the best in his future endeavors."
"I will be transitioning from my role as Chief Executive Officer and President on November 1 and look forward to my next exciting chapters in the healthcare world. I believe strongly in CareDx's patient-centric mission, and I am extremely proud of what we have accomplished together," said Dr. Seeto. "I wish the team well and look forward to continuing to support the Company's important work in my new role as Senior Advisor to the Chairperson."
CareDx delivered strong financial and operational performance in the third quarter and has decided to raise its full year 2023 revenue guidance to be in the range of $274 to $278 million. CareDx will provide more information during its third quarter earnings call to be held on November 8, 2023, 1:30pm Pacific Time, 4:30pm Eastern Time.
Posted In: CDNA